Recruiting · registry status

Testing a milk thistle extract for Parkinson’s symptoms

Researchers investigate whether silymarin, a substance from milk thistle, affects Parkinson’s symptoms. Any benefit remains to be established.

Testing a treatment or activity · Study reference: NCT07001150

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date): 2025-05-10
Main measurements finished (planned): 2026-05-30
Study finished (planned): 2026-05-30

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded

2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 45 years to 65 years · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: * Age between 45 and 65 years old * Both sexes * Patients with Parkinson's disease on dopamine replacement therapy * Modified Hoehn and Yahr stage, MHY 1-4 (29) Exclusion Criteria: * Subjects \< 18 years of age * Pregnant or breastfeeding women * Suspected hypersensitivity to silymarin or multivitamins * Advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy) * Subjects with morbid obesity, i.e., a Body Mass Index (BMI) \> 40 * Subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with Hemoglobin A1C (HbA1C)\>7% * Current use of Silymarin or recent use within the past two weeks. * Other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.

Full study name & original research details

Official study title

Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Short title used by the registry

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Original description

Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.

Conditions reported: Parkinson Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

ClinicalTrials.gov · NCT07001150 ↗ — RECRUITING; checked 2026-10-13
ClinicalTrials.gov · NCT07001150 ↗ — Recruiting; WHO ICTRP processed 2025-09-22; checked 2026-10-13

Study type: Interventional
Interventions: levodopa-carbidopa; Silymarin
Phases: PHASE2
Sponsor: Tanta University
Start date reported by registry: 2025-05-10 (actual)

Registry updated: 2025-09-10 · Status last verified by the registry submitter: 2025-09

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Nour Elsherbeny, MSc · 01286911189 · nelsherbeny@horus.edu.eg

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Tanta Hospital for Mental Health

Tanta, Tanta, Qism 2, Egypt

Recruiting

Nour A Elsherbeny, Bachelor of Pharmacy · 01286911189 · nelsherbeny@horus.edu.eg

Nour A Elsherbeny, Bachelor of Pharmacy

Facility not reported

Egypt

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.